Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

998 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Meher N, Ashley GW, Bobba KN, Wadhwa A, Bidkar AP, Dasari C, Mu C, Sankaranarayanan RA, Serrano JAC, Raveendran A, Bulkley DP, Aggarwal R, Greenland NY, Oskowitz A, Wilson DM, Seo Y, Santi DV, VanBrocklin HF, Flavell RR. Meher N, et al. Among authors: wilson dm. Adv Healthc Mater. 2024 May 3:e2304618. doi: 10.1002/adhm.202304618. Online ahead of print. Adv Healthc Mater. 2024. PMID: 38700450
Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.
Meher N, Ashley GW, Bidkar AP, Dhrona S, Fong C, Fontaine SD, Beckford Vera DR, Wilson DM, Seo Y, Santi DV, VanBrocklin HF, Flavell RR. Meher N, et al. Among authors: wilson dm. ACS Appl Mater Interfaces. 2022 Nov 16;14(45):50569-50582. doi: 10.1021/acsami.2c15095. Epub 2022 Nov 1. ACS Appl Mater Interfaces. 2022. PMID: 36318757 Free PMC article.
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. Wang S, et al. Among authors: wilson dm. Mol Pharm. 2019 Sep 3;16(9):3831-3841. doi: 10.1021/acs.molpharmaceut.9b00464. Epub 2019 Aug 16. Mol Pharm. 2019. PMID: 31381351 Free PMC article.
Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
Meher N, Seo K, Wang S, Bidkar AP, Fogarty M, Dhrona S, Huang X, Tang R, Blaha C, Evans MJ, Raleigh DR, Jun YW, VanBrocklin HF, Desai TA, Wilson DM, Ozawa T, Flavell RR. Meher N, et al. Among authors: wilson dm. ACS Appl Mater Interfaces. 2021 Nov 24;13(46):54739-54752. doi: 10.1021/acsami.1c16383. Epub 2021 Nov 9. ACS Appl Mater Interfaces. 2021. PMID: 34752058
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Chou J, Liu B, Flavell RR. Bidkar AP, et al. Among authors: wilson dm. Clin Cancer Res. 2023 May 15;29(10):1916-1928. doi: 10.1158/1078-0432.CCR-22-3291. Clin Cancer Res. 2023. PMID: 36917693 Free PMC article.
Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac α-Radiotherapeutics.
Bobba KN, Bidkar AP, Meher N, Fong C, Wadhwa A, Dhrona S, Sorlin A, Bidlingmaier S, Shuere B, He J, Wilson DM, Liu B, Seo Y, VanBrocklin HF, Flavell RR. Bobba KN, et al. Among authors: wilson dm. J Nucl Med. 2023 Jul;64(7):1076-1082. doi: 10.2967/jnumed.122.265355. Epub 2023 May 18. J Nucl Med. 2023. PMID: 37201957 Free PMC article.
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. Wadhwa A, et al. Among authors: wilson dm. Clin Cancer Res. 2024 Mar 1;30(5):1009-1021. doi: 10.1158/1078-0432.CCR-23-2130. Clin Cancer Res. 2024. PMID: 38109209 Free PMC article.
Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. Bobba KN, et al. Among authors: wilson dm. Theranostics. 2024 Jan 27;14(4):1344-1360. doi: 10.7150/thno.92742. eCollection 2024. Theranostics. 2024. PMID: 38389832 Free PMC article.
998 results